Similarities of incretin-based therapies
Properties/action | Incretin mimetics | DPP-4 inhibitors |
---|---|---|
Glucose-dependent insulin secretion | Yes | Yes |
Glucose-dependent glucagonostatic effect | Yes | Yes |
Effect on fasting plasma glucose (reduction) | By 1.4–3.4 mmol/l | By 1.0–1.4 mmol/l |
Effect on postprandial glucose | Yes | Yes (but weaker) |
Effect on A1C (reduction) | By 0.8–1.8% | By 0.5–1.1% |
Effect on (pro)insulin biosynthesis | Yes | Yes (weaker?) |
Improved in vivo β-cell function (in humans) | Yes* | Yes* |
Beneficial cardiovascular effects | Probable | Not proven |
↵*As determined while patients received treatment (lasting effects need to be proven after washing out treatment).